查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1554191

暴发性抗磷脂抗体症候群市场规模、份额和趋势分析报告：按治疗、最终用途、地区和细分市场预测，2024-2030 年

Catastrophic Antiphospholipid Syndrome Market Size, Share & Trends Analysis Report By Treatment (Anticoagulants, Immunosuppressive Therapy, Plasma Exchange Therapy), By End-use (Hospitals, Clinics), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

暴发性抗磷脂抗体症候群市场成长与趋势：

Grand View Research最新报告显示，预计到2030年，全球暴发性抗磷脂抗体症候群市场规模将达到89.9亿美元，2024年至2030年复合年增长率为10.7%，预计将持续成长。

该市场涵盖与这种罕见且危及生命的自体免疫疾病的诊断、治疗和管理相关的各个方面。

在致命性抗磷脂症候群 (CAPS) 市场中，对有效治疗方案的需求不断增长，这一点意义重大。患者和医疗保健提供者正在积极寻求创新的治疗方法，以应对 CAPS 带来的独特挑战，包括快速进展和多系统参与。临床试验的重点是开发标靶治疗，以减少与该综合征相关的严重血栓事件。

自体免疫疾病盛行率的上升预计将推动市场成长。自体免疫疾病涉及异常的免疫反应，其中身体错误地攻击组织。 APS 是一种自体免疫疾病，可导致併发症，包括大肠激躁症(IBS) 等消化器官系统问题。根据克隆氏症和加拿大结肠炎协会的数据，预计到 2023 年，将有超过 322,600 名加拿大人患有发炎性肠道疾病(IBD)，约占总人口的 0.82%。

暴发性抗磷脂抗体症候群市场报告亮点

  • 根据治疗方法，静脉注射免疫球蛋白（IVIG）细分市场在 2023 年以 36.93% 的最大销售份额引领市场。 IVIG 的疗效得到了各种临床病例的支持，在这些病例中，难治性 CAPS 患者在接受这种治疗并结合抗凝血治疗和皮质类固醇等其他治疗后，病情有所改善。
  • 按最终用途划分，医院业以 2023 年 62.80% 的最大销售份额引领市场。鑑于自体免疫疾病的盛行率不断增加以及医疗保健提供者对CAPS 的认识不断提高，及时干预可以显着改善患者的治疗效果并降低与这种危及生命的疾病相关的死亡率，因为它可以降低死亡率。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章暴发性抗磷脂抗体症候群市场的变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 暴发性抗磷脂抗体症候群市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第 4 章 暴发性抗磷脂抗体症候群市场：依治疗方法估计与趋势分析

  • 全球暴发性抗磷脂抗体症候群市场：治疗仪表板
  • 全球暴发性抗磷脂抗体症候群市场：治疗变异分析
  • 全球暴发性抗磷脂抗体症候群市场：按治疗分類的收益
  • 抗凝血物
  • 免疫抑制治疗
  • 血浆交换疗法（血浆交换疗法）
  • 静脉注射免疫球蛋白 (IVIG)
  • 其他治疗

第五章 暴发性抗磷脂抗体症候群市场：依最终用途分类的估计与趋势分析

  • 全球暴发性抗磷脂抗体症候群市场：最终用途仪表板
  • 全球暴发性抗磷脂抗体症候群市场：最终用途变化分析
  • 按最终用途分類的收益
  • 医院
  • 诊所
  • 其他的

第六章 爆发性抗磷脂抗体症候群市场：依治疗和最终用途的区域估计和趋势分析

  • 区域仪表板
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第七章 竞争格局

  • 公司/竞争对手分类
  • 供应商情况
    • 主要经销商及通路伙伴名单
    • 2023年主要企业市场占有率分析
    • Pfizer
    • Abbott
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • Boehringer Ingelheim International GmbH
    • Novartis AG
    • Merck KGaA
    • AbbVie Inc.
    • F. Hoffmann-La Roche
    • Johnson &Johnson Services, Inc.
Product Code: GVR-4-68040-425-0

Catastrophic Antiphospholipid Syndrome Market Growth & Trends:

The global catastrophic antiphospholipid syndrome market size is anticipated to reach USD 8.99 billion by 2030 and is projected to grow at a CAGR of 10.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market encompasses various aspects related to the diagnosis, treatment, and management of this rare and life-threatening autoimmune disorder.

The rising demand for effective treatment options is critical in the catastrophic antiphospholipid syndrome (CAPS) market. Patients and healthcare providers are actively seeking innovative therapies that can address the unique challenges posed by CAPS, including its rapid progression and multi-organ involvement. The clinical trials are focused on developing targeted therapies that mitigate the severe thrombotic events associated with the syndrome.

The rising prevalence of autoimmune disorders is anticipated to drive the market growth. Autoimmune disorders involve an abnormal immune response where the body mistakenly attacks its tissues. APS, a type of autoimmune disease, can lead to complications, including digestive issues such as irritable bowel syndrome (IBS). According to Crohn's and Colitis Canada, over 322,600 Canadians were estimated to be living with inflammatory bowel disease (IBD) in 2023, which represents about 0.82% of the total population.

Catastrophic Antiphospholipid Syndrome Market Report Highlights:

  • Based on treatment, the intravenous immunoglobulin (IVIG) segment led the market with the largest revenue share of 36.93% in 2023. The efficacy of IVIG is supported by various clinical instances where patients with refractory CAPS showed improvement after receiving this therapy, often in conjunction with other treatments such as anticoagulation and corticosteroids
  • Based on end-use, the hospital segment led the market with the largest revenue share of 62.80% in 2023. The increasing prevalence of autoimmune diseases and the growing awareness of CAPS among healthcare providers fuel the demand for hospital-based care, as timely interventions can significantly improve patient outcomes and reduce mortality rates associated with this life-threatening condition

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. End Use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment Outlook
    • 2.2.2. End Use Outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Catastrophic Antiphospholipid Syndrome Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. The rising incidence of autoimmune diseases
      • 3.2.1.2. Advancements in diagnostic technologies
      • 3.2.1.3. Increased awareness and education about CAPS
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Limited awareness and understanding of CAPS
      • 3.2.2.2. Challenges in the diagnosis and treatment of CAPS
  • 3.3. Catastrophic Antiphospholipid Syndrome Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Catastrophic Antiphospholipid Syndrome Market: Treatments Estimates & Trend Analysis

  • 4.1. Global Catastrophic Antiphospholipid Syndrome Market: Treatments Dashboard
  • 4.2. Global Catastrophic Antiphospholipid Syndrome Market: Treatments Movement Analysis
  • 4.3. Global Catastrophic Antiphospholipid Syndrome Market by Treatments, Revenue
  • 4.4. Anticoagulants
    • 4.4.1. Anticoagulants market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Immunosuppressive Therapy
    • 4.5.1. Immunosuppressive Therapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Plasma Exchange Therapy (Plasmapheresis)
    • 4.6.1. Plasma Exchange Therapy (Plasmapheresis) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Intravenous Immunoglobulin (IVIG)
    • 4.7.1. Intravenous Immunoglobulin (IVIG) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Other Treatment
    • 4.8.1. Other treatment market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Catastrophic Antiphospholipid Syndrome Market: End Use Estimates & Trend Analysis

  • 5.1. Global Catastrophic Antiphospholipid Syndrome Market: End Use Dashboard
  • 5.2. Global Catastrophic Antiphospholipid Syndrome Market: End Use Movement Analysis
  • 5.3. Global Catastrophic Antiphospholipid Syndrome Market Estimates and Forecasts, By End Use, Revenue (USD Million)
  • 5.4. Hospitals
    • 5.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Clinics
    • 5.5.1. Clinics market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Other
    • 5.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Catastrophic Antiphospholipid Syndrome Market: Regional Estimates & Trend Analysis by Treatments, and End Use

  • 6.1. Regional Dashboard
  • 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework/ reimbursement structure
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/ reimbursement structure
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.3. Mexico
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Regulatory framework/ reimbursement structure
      • 6.3.3.3. Competitive scenario
      • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. France
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework/ reimbursement structure
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework/ reimbursement structure
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Norway
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework/ reimbursement structure
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Regulatory framework/ reimbursement structure
      • 6.4.7.3. Competitive scenario
      • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Regulatory framework/ reimbursement structure
      • 6.4.8.3. Competitive scenario
      • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. India
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.5. South Korea
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.6. Thailand
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Argentina
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company/Competition Categorization
  • 7.2. Vendor Landscape
    • 7.2.1. List of key distributors and channel partners
    • 7.2.2. Key company market share analysis, 2023
    • 7.2.3. Pfizer
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Abbott
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Bristol-Myers Squibb Company
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Eli Lilly and Company
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Boehringer Ingelheim International GmbH
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Novartis AG
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. Merck KGaA
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. AbbVie Inc.
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives
    • 7.2.11. F. Hoffmann-La Roche
      • 7.2.11.1. Company overview
      • 7.2.11.2. Financial performance
      • 7.2.11.3. Product benchmarking
      • 7.2.11.4. Strategic initiatives
    • 7.2.12. Johnson & Johnson Services, Inc.
      • 7.2.12.1. Company overview
      • 7.2.12.2. Financial performance
      • 7.2.12.3. Product benchmarking
      • 7.2.12.4. Strategic initiatives

List of Tables

  • Table 1. List of abbreviation
  • Table 2. North America Catastrophic antiphospholipid syndrome market, by region, 2018 - 2030 (USD Million)
  • Table 3. North America Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 4. North America Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 5. U.S. Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 6. U.S. Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 7. Canada Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 8. Canada Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 9. Mexico Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 10. Mexico Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 11. Europe Catastrophic antiphospholipid syndrome market, by region, 2018 - 2030 (USD Million)
  • Table 12. Europe Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 13. Europe Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 14. Germany Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 15. Germany Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 16. UK Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 17. UK Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 18. France Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 19. France Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 20. Italy Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 21. Italy Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 22. Spain Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 23. Spain Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 24. Denmark Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 25. Denmark Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 26. Sweden Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 27. Sweden Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 28. Norway Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 29. Norway Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 30. Asia Pacific Catastrophic antiphospholipid syndrome market, by region, 2018 - 2030 (USD Million)
  • Table 31. Asia Pacific Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 32. Asia Pacific Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 33. China Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 34. China Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 35. Japan Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 36. Japan Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 37. India Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 38. India Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 39. South Korea Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 40. South Korea Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 41. Australia Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 42. Australia Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 43. Thailand Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 44. Thailand Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 45. Latin America Catastrophic antiphospholipid syndrome market, by region, 2018 - 2030 (USD Million)
  • Table 46. Latin America Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 47. Latin America Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 48. Brazil Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 49. Brazil Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 50. Argentina Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 51. Argentina Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 52. MEA Catastrophic antiphospholipid syndrome market, by region, 2018 - 2030 (USD Million)
  • Table 53. MEA Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 54. MEA Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 55. South Africa Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 56. South Africa Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 57. Saudi Arabia Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 58. Saudi Arabia Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 59. UAE Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 60. UAE Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 61. Kuwait Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 62. Kuwait Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Market research approaches
  • Fig. 4 QFD modeling for market share assessment
  • Fig. 5 Market formulation & validation
  • Fig. 6 Catastrophic antiphospholipid syndrome market: market outlook
  • Fig. 7 Catastrophic antiphospholipid syndrome competitive insights
  • Fig. 8 Parent market outlook
  • Fig. 9 Related/ancillary market outlook
  • Fig. 10 Catastrophic antiphospholipid syndrome market driver impact
  • Fig. 11 Catastrophic antiphospholipid syndrome market restraint impact
  • Fig. 12 Catastrophic antiphospholipid syndrome market: Treatment movement analysis
  • Fig. 13 Catastrophic antiphospholipid syndrome market: Treatment outlook and key takeaways
  • Fig. 14 Anticoagulants market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 15 Immunosuppressive therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 16 Plasma exchange therapy (plasmapheresis) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 17 Intravenous immunoglobulin (IVIG) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Other treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Catastrophic antiphospholipid syndrome market: End Use movement analysis
  • Fig. 20 Catastrophic antiphospholipid syndrome market: End Use outlook and key takeaways
  • Fig. 21 Hospitals market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Clinics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Other market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Global catastrophic antiphospholipid syndrome market: Regional movement analysis
  • Fig. 25 Global catastrophic antiphospholipid syndrome market: Regional outlook and key takeaways
  • Fig. 26 Global catastrophic antiphospholipid syndrome market share and leading players
  • Fig. 27 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. key country dynamics
  • Fig. 29 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Canada key country dynamics
  • Fig. 31 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Mexico key country dynamics
  • Fig. 33 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 UK key country dynamics
  • Fig. 36 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Germany key country dynamics
  • Fig. 38 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 France key country dynamics
  • Fig. 40 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Italy key country dynamics
  • Fig. 42 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Spain key country dynamics
  • Fig. 44 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Denmark key country dynamics
  • Fig. 46 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Sweden key country dynamics
  • Fig. 48 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Norway key country dynamics
  • Fig. 50 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 China key country dynamics
  • Fig. 53 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Japan key country dynamics
  • Fig. 55 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 India key country dynamics
  • Fig. 57 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Thailand key country dynamics
  • Fig. 59 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 South Korea key country dynamics
  • Fig. 61 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Australia key country dynamics
  • Fig. 63 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Brazil key country dynamics
  • Fig. 66 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Argentina key country dynamics
  • Fig. 68 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 South Africa key country dynamics
  • Fig. 71 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Saudi Arabia key country dynamics
  • Fig. 73 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 UAE key country dynamics
  • Fig. 75 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Kuwait key country dynamics
  • Fig. 77 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Market share of key market players - Catastrophic antiphospholipid syndrome market